Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Cite this paper

@article{OConnor2005PhaseIC, title={Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.}, author={Owen O'Connor and J. J. Wright and Craig H. Moskowitz and Jamie Muzzy and Barbara Macgregor-Cortelli and Michael Dean Stubblefield and David J. Straus and Carol S. Portlock and Paul A. Hamlin and Elizabeth S Choi and Otila Dumetrescu and Dixie L Esseltine and Elizabeth G. Trehu and Julian Adams and David P. Schenkein and Andrew D. Zelenetz}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2005}, volume={23 4}, pages={676-84} }